News

04.12.2017

“Precision medicine is the best opportunity to reconfigure healthcare”

“Precision medicine is the best opportunity to reconfigure healthcare”

After 20 years with the pharmaceutical company Eli Lilly, Bernard Munos set out to better understand pharmaceutical innovation – specifically what makes it possible and how to get more of it. Munos is now a Senior Fellow at Faster Cures, a Center of the Milken Institute, and the founder of the consultancy InnoThink, which advises biomedical research organizations on how to become better innovators. He also contributes to Forbes magazine, an American business publication. Munos travelled to Basel in October, on behalf of HKBB and DayOne to participate in the “Powertalk”.

mehr >
14.12.2017

VR, AR, mixed – three words for reality

VR, AR, mixed – three words for reality

Revolution, tsunami... there are various expressions to describe augmented reality, virtual reality and also mixed reality. The terms are clear for researchers who have been using these technologies for 15 years, but for average users many things will change.

mehr >
11.12.2017

Roche Diagnostics is a top employer

Roche Diagnostics is a top employer

Employees have recognized the Basel-based pharmaceutical company Roche Diagnostics as one of the best places to work. Current as well as former employees were invited to provide feedback.

mehr >
06.11.2017

“We want to improve the visibility of startups at the University of Basel”

“We want to improve the visibility of startups at the University of Basel”

Christian Elias Schneider has been Head of Innovation at the University of Basel for eight months now. His job is to promote entrepreneurship and projects in collaboration with industry.

mehr >
07.12.2017

UNESCO recognizes Basel Fasnacht as intangible heritage

UNESCO recognizes Basel Fasnacht as intangible heritage

Basel Fasnacht was on Thursday inscribed onto UNESCO’s intangible cultural heritage of humanity list. The decision underlines the importance of the Basel dialect.

mehr >
06.12.2017

Genentech receives approval for brain cancer treatment

Genentech, a subsidiary of Roche, has received full approval in the U.S. for Avastin, which is used to treat one of the most aggressive forms of brain cancer.

mehr >
03.10.2017

"You should always have something crazy cooking on the back burner"

When Jennifer Doudna gave her keynote at Basel Life in September, the auditorium in the Congress Center was packed. Susan Gasser, Professor of Molecular Biology at the University of Basel introduced Doudna as groundbreaking and extremely innovative. The Professor of Chemistry and of Molecular and Cell Biology at the University of California, Berkeley was on top of Gassers wish list for the Basel Life. The leading figure of what is known as the CRISPR revolution among scientists sat down with BaselArea.swiss during her stay in Basel to talk about her lab, flexible career paths and what makes a great researcher.

mehr >
05.12.2017

The revolution comes from outside

The revolution comes from outside

On November 15th, the second DayOne Conference “Designing the future of health” took place at Markthalle Basel. More than 250 experts accepted the invitation to listen to interesting keynotes, discuss with panelists and support entrepreneurs in developing their projects.

mehr >
05.12.2017

Yannick Guerdat : une success story made in Jura

Yannick Guerdat et son chien Diva qui l’accompagne chaque jour au bureau.

Il n’y a pas que les grandes marques emblématiques telles qu’Apple ou Google qui ont été imaginées et conçues au fond d’un garage. Au Jura, c’est dans sa chambre d’adolescent, avec beaucoup de passion, de détermination et de persévérance que Yannick Guerdat a imaginé puis créé son entreprise Artionet. Aujourd’hui, après 16 années d’existence et plus de 1500 sites web actifs, l’agence de Web design basée à Delémont, au Jura, a déjà parcouru son bonhomme de chemin. Actuellement, l’entreprise occupe une jeune équipe de plus de 20 employés à temps complet.

mehr >
29.09.2017

Spirochem opens new state-­of-­the-­art Services and R&D facilities in Basel

Spirochem opens new state-­of-­the-­art Services and R&D facilities in Basel

Basel – The fine chemicals company SpiroChem has relocated to state-of-the-art facilities in the Rosental area of Basel, offering the company an ideal location to significantly expand its operations. SpiroChem has also strengthened its board of directors.

mehr >
04.12.2017

Shanghai Biotalk: From Shanghai to Basel

Shanghai Biotalk

Around 50 people joined the “Shanghai Biotalk” event on November 8th in Shanghai to discuss strategies and challenges for Chinese pharmaceutical companies entering the European market. Andre Guedel from KPMG stressed the importance of a strategic approach when introducing biopharmaceutical products to Europe. A successful strategy should include all relevant aspects such as reimbursement, target operating model, site selection, taxes and regulatory environment. A big highlight of the event was a keynote by Sammy Jiang, Vice President of Luye Pharma Group. She talked about her company’s global strategy and how Luye Pharma leverages its hub in Basel to expand to the European market. Luye Pharma is one of China’s most innovative and international pharma companies.

mehr >
04.12.2017

Sensors – a fantastic event about hardware, machine learning and humans

The interested audience at Halle 7 at Gundeldingerfeld.

“It is a slow tsunami.” Matthias Krieger, CSEM, used this expression when he described the development of sensors, the Internet-of-Things (IoT) and machine learning. BaselArea’s event “Sensors – key elements in the new world of digitalization”, which took place on November 14th at Halle 7 at the Gundeldingerfeld in Basel, covered a fascinating field ranging from sensor hardware to wireless data communication, machine learning and the difficult field of human-machine interface.

mehr >
18.09.2017

13 startup projects qualify for the first phase of BaseLaunch

13 startup projects qualify for the first phase of BaseLaunch

The BaseLaunch Healthcare Accelerator program from BaselArea.swiss started on September 14. Over 100 applications were received from more than 30 countries, and the selection committee has selected 13 projects to go on to Phase I. Now, the project teams will work with industry experts to further develop their business case over the next three months.

mehr >
04.12.2017

Idorsia to collaborate with Janssen Biotech

Idorsia to collaborate with Janssen Biotech

Idorsia is set to receive a milestone payment in the amount of $230 million from Janssen Biotech Inc. A subsidiary of Johnson & Johnson, Janssen intends to collaborate with Idorsia to commercialize a drug for treating hypertension.

mehr >
01.12.2017

Basilea extends cooperation with Pfizer

Basilea extends cooperation with Pfizer

The Basel-based pharmaceutical company Basilea has extended its existing licence agreement with Pfizer for the anti-fungual Cresemba to include China and several other countries. This makes Basilea eligible to receive milestone payments and improves its financial outlook.

mehr >
05.09.2017

"In Switzerland, we often sell promising technologies too early"

Ulf Claesson is a "serial entrepreneur". During the past 25 years, he has set up companies that have gone on to become firmly established in the market. In 2012, he joined Clinerion as CEO and shareholder. Since then, the company has positioned itself in the medical data field and recently entered into a partnership with British company Cisiv. Clinerion's software helps recruit patients for clinical trials run by major pharmaceutical companies – in real time. But the competition never sleeps. A growing number of competitors is now appearing, especially in the USA where there is no shortage of risk capital. In this interview for the Innovation Report, Claesson explains how the Basel-based healthtech company plans to maintain its leadership position.

mehr >
30.11.2017

Novartis medication effective against psoriasis

Novartis medication effective against psoriasis

The Basel-based pharmaceutical company Novartis has released positive data on the long-term efficacy of its medication Cosentyx, which is used for hard-to-treat types of psoriasis.

mehr >
27.11.2017

Roche looks to further expand its digital portfolio

Roche looks to further expand its digital portfolio

The Basel-based pharmaceutical company Roche has already invested heavily in digital diagnostics – and it will continue to do so, said Roche’s head of diagnostics, Roland Diggelmann.

mehr >
04.07.2017

"I want to turn innovative research into new drugs"

Cellestia CEO Michael Bauer.

Each year some 250,000 patients develop a type of cancer because of faulty communication between cells. This malfunction occurs in what is known as the NOTCH signal path. There are currently no effective treatments – but this is set to change. Cellestia Biotech AG is developing an innovative drug against this type of cancer by using a novel active ingredient that selectively attacks the malfunctioning cell communication. The drug could be used to treat leukaemia, lymphomas and solid tumours such as breast cancer.

mehr >
24.11.2017

Clariant develops new growth strategy

Clariant develops new growth strategy

Clariant’s Board of Directors has approved a plan to define a concrete set of measures to enhance value creation, which could include acquisitions. An agreement has yet to be reached with the major shareholder White Tale.

mehr >
23.11.2017

FutureHealth Basel to re-think healthcare system

FutureHealth Basel to re-think healthcare system

The Swiss Economic Forum and the Basel Chamber of Commerce want to make the Swiss life sciences and healthcare industries sustainable. Set to support the proposal is FutureHealth Basel, which will bring together 250 key industry players in January.

mehr >
13.06.2017

Roivant is creating a buzz in Basel

Roivant is creating a buzz in Basel

Roivant Sciences, a fast-growing life sciences company from the US, recently opened its global headquarters in Basel. In celebration of their newly established location, Roivant, together with BaselArea.swiss, invited stakeholders from the life sciences sector to “Halle 7, Gundeldingerfeld” in Basel on June 8th 2017 for a panel discussion on the future of healthcare.

mehr >
22.11.2017

Pharmaceutical industry is driving the Swiss economy

Pharmaceutical industry is driving the Swiss economy

The number of jobs in the pharmaceutical industry is on a steady rise – and other industries are benefiting from the success of the pharmaceutical companies. According to a new study from BAK Economics, the pharmaceutical industry is the most important driver of growth in Switzerland as a centre of industry.

mehr >
21.11.2017

Basel Chamber of Commerce supports digitalization

Basel Chamber of Commerce supports digitalization

The Basel Chamber of Commerce would like to support companies with the digital transformation. To this end, it launched the initiative Are you digital? and is covering three-quarters of the costs of the ‘digital check-up’ for its members. The response has been very positive to date.

mehr >
08.06.2017

BaselArea.swiss got off to a successful start

BaselArea.swiss got off to a successful start

In its first annual report, the newly formed BaselArea.swiss can look back on a successful 2016. The joint initiative for innovation and economic promotion by the cantons of Basel-Stadt, Basel-Landschaft and Jura succeeded in growing in all areas. It provided assistance to 36 companies moving to the region, which corresponds to a 50% increase over the previous year. In the area of innovation promotion, over 4,000 participants attended 80 events, expanding the regional network from 8,000 to 13,000 innovators and experts. The services provided by BaselArea.swiss were also actively used to promote start-up projects, contributing to 43 companies being founded.

mehr >
21.11.2017

The powerful patient

The powerful patient

The Life Sciences Leader Forum #4 focused on the topic of the emerging digitalization in the health care system. The event that took place on November 8th in Basel provided a lot of interesting discussion points and insights from leaders in their respective fields. There is no doubt that the patient is in the focus of precision medicine: Patient convenience is on the rise, with better possibilities for the whole process from making appointments to transfer of knowledge and guidance.

mehr >
20.11.2017

KPMG becomes BaseLaunch partner

KPMG becomes BaseLaunch partner

The healthcare accelerator program BaseLaunch from BaselArea.swiss, supports startups from the healthcare sector. In addition to prominent pharmaceutical companies, it can now count the consultancy firm KPMG as one of its partners.

mehr >
08.06.2017

A molecular assembly line to cure the body

A molecular assembly line to cure the body

Imagine that certain forms of blindness could be cured. Or imagine that the body itself could produce a cure for some of its own diseases. These may be just some of the results of the National Centre of Competence in Research Molecular Systems Engineering (NCCR MSE). Its long-term goals are to create molecular systems and factories for the production of high added-value chemicals and develop cellular systems for new applications in medical diagnostics, therapy and treatment. Director Thomas Ward is aiming high: He wants to make Basel the leading hub for the next European flagship project. At stake: one billion euro.

mehr >
17.11.2017

Roche to acquire analytics firm

Roche to acquire analytics firm

The Basel-based pharmaceutical company Roche will acquire the U.S. data analytics firm Viewics, allowing Roche to add further digital capabilities along its laboratory value chain.

mehr >
16.11.2017

Myovant Sciences increases research expenses

The Basel-based pharmaceutical company Myovant Sciences reduced its net loss in the second quarter by just under five million dollars compared to the previous year. It significantly increased its research and development expenses.

mehr >
15.05.2017

Investing in strengths – Swiss leadership in life sciences

Investing in strengths – Swiss leadership in life sciences

How can Switzerland and the Basel region maintain their international leadership role in life sciences? As part of the Biotech and Digitization Day, Federal Councillor Johann Schneider-Ammann visited the Basel region to discuss current trends and challenges with a high-ranking delegation from politics, business, research and start-ups.

mehr >
15.11.2017

Basel attracts international professionals

Basel, copyright: Andreas Zimmermann

Basel – Basel is the most attractive city in Switzerland for professionals from abroad. In the latest Expat City Ranking, Basel came ahead of both Zurich and Geneva and ranks among the top 10 in the world.

mehr >
13.11.2017

Novartis presents current state of research

Novartis presents current state of research

Novartis presented recent developments in its research programme to investors in London, including positive results for its ophthalmology treatment RTH258.

mehr >
09.05.2017

The healthcare system must take responsibility

The healthcare system must take responsibility

Kristian Schneider wants to improve the quality of health care and better manage the rising healthcare costs by means of a network that includes doctors, hospitals, insurance companies and the state. Its aim is to provide exactly those services needed for the health of patients. For the canton of Jura, which like all other cantons suffers from the fragmentation of service providers, this could be a unique opportunity to build an integrative care system – and thus become a pioneer, says the director of Hôpital du Jura.

mehr >
10.11.2017

Myovant drug performs well in study

Myovant drug performs well in study

The Basel-based pharmaceutical company Myovant Sciences has announced positive results from a study evaluating relugolix. The drug performed well in efficacy and safety for the treatment of uterine fibroids.

mehr >
09.11.2017

Evolva secures further development

Evolva secures further development

The ingredients manufacturer Evolva has secured gross revenue of more than 80 million Swiss francs through the offering of new shares. The company now plans to focus on the commercial success of three products.

mehr >
21.04.2017

Basel-Landschaft welcomes new companies

Basel-Landschaft welcomes new companies

The canton of Basel-Landschaft welcomed a host of new companies over the past few weeks. BaselArea.swiss played in a big role in attracting the companies to establish themselves in Basel.

mehr >
07.11.2017

Swissbau Innovation Lab: Interaktive Einblicke ins digitale Bauen

Swissbau Innovation Lab: Interaktive Einblicke ins digitale Bauen

Vom 16. bis zum 20. Januar 2018 findet in Basel die Swissbau statt, die grösste Schweizer Baumesse. Dabei spielt die Digitalisierung in der Bauwirtschaft eine tragende Rolle: Die neue Sonderschau Swissbau Innovation Lab macht die Chancen der digitalen Transformation in der Bauwirtschaft erlebbar. Ziel ist es, die Marktteilnehmer besser miteinander zu vernetzen und all jene zusammenzubringen, die am Bauprozess beteiligt sind. Dies erleichtert den Dialog und stärkt Innovationskraft sowie Wettbewerbsfähigkeit. Eine führende Rolle bei der Entwicklung der Inhalte übernimmt die Interessengemeinschaft Bauen digital Schweiz. Darüber hinaus engagiert sich KTI – die Kommission für Technologie und Innovation des Bundes – als Förderer und Katalysator für Innovationen im KMU-Bereich. Die Hochschule für Architektur, Bau und Geomatik FHNW ist Research und Planning Partner des Innovation Lab.

mehr >
07.11.2017

Basel economy confirms positive trends

Basel economy confirms positive trends

Around 80 per cent of companies in Basel rate the current course of business as satisfactory or even good. This positive mood is even more pronounced in the life sciences sector, according to a survey conducted by the Basel Chamber of Commerce.

mehr >
12.04.2017

“I see a very innovation-friendly climate in Basel”

“I see a very innovation-friendly climate in Basel”

It all began with research resources that were a quarter of a century old. Simon Ittig and his colleagues at the Biozentrum of the University of Basel turned these into a research project – and eventually a start-up. T3 Pharmaceuticals develops new therapies to treat solid tumours.

mehr >

 

(Source: http://www.baselarea.swiss/en/baselarea-swiss/channels/innovation-report.html)